Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 29Myelodysplastic Syndromes 10Advanced Solid Tumors 8Leukemia, Myelomonocytic, Chronic 6Myeloproliferative Disorders 5Advanced Solid Tumor 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Neoplasms 4Advanced Solid Tumour 4Multiple Myeloma 3Lung Neoplasms 3Leukemia, Monocytic, Acute 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Thrombocythemia, Essential 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Small Cell Lung Carcinoma 2Recurrence 2Prostatic Neoplasms 2Primary Myelofibrosis 2Polycythemia Vera 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Acute 2Leukemia, Biphenotypic, Acute 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Malignant Solid Tumor 2

Interventions

Cyclophosphamide 25fludarabine 19Dexamethasone 17pembrolizumab 13Rituximab 12venetoclax 9Lenalidomide 9Gemcitabine 9Etoposide 9pomalidomide 8Vincristine 7glofitamab 6fludarabine phosphate 6carfilzomib 6Temozolomide 6obinutuzumab 5daratumumab 5Prednisone 5Nivolumab 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5Bortezomib 5zanubrutinib 4selinexor 4Immunotherapy, Adoptive 4Cytarabine 4Carboplatin 4Azacitidine 4ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Injections × 90 days × Clear all
NCT05564650 2026-05-19

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Thomas Jefferson University

Phase 1 Completed
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡